EUVIMEDEUVIMED entdecken
Systematische Übersicht

Microdosing Psychedelics: A Systematic Review of Human Studies and Registered Clinical Trials

Arun Chinna‐Meyyappan, Erica S. Kaczmarek, Sajad Sajad, Joshua Rosenblat

Libraries and Cultural Resources (University of Calgary) · 01.01.2025

DOI: 10.11575/prism/51859 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Libraries and Cultural Resources (University of Calgary), erschienen am 01.01.2025. Verfasst von Arun Chinna‐Meyyappan und 3 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Microdosing psychedelics refers to the regular administration of sub-perceptual doses of classical serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (LSD). This practice has gained widespread attention for its potential effects on mood, cognition, and wellbeing. Despite growing public and scientific interest, empirical evidence on microdosing remains fragmented across heterogeneous study designs, and methodological rigor varies substantially across studies. This systematic review aims to comprehensively synthesize published and registered human studies on psychedelic microdosing to evaluate current findings, methodological quality, and gaps in the literature.

Methods

A comprehensive literature search was conducted across PubMed, PsycINFO, Embase, and ClinicalTrials.gov from database inception to July 22, 2025. Search terms combined concepts related to psychedelics and low-dose or microdosing administration. Eligible studies included human adults (?18 years) undergoing repeated sub-perceptual dosing of classical serotonergic psychedelics (psilocybin, LSD, DMT, mescaline, or ayahuasca). Both peer-reviewed publications and registered clinical trials were included. Screening and data extraction were performed independently by three reviewers using Covidence. Risk of bias was assessed using appropriate design-specific tools (RoB 2, ROBINS-I, and JBI checklists). Given the heterogeneity of outcomes, a narrative synthesis was conducted across domains of psychological and cognitive outcomes, wellbeing and quality of life, physiological and neurobiological measures, subjective experiences, and safety.

Results

From 1,218 records identified, 67 studies met inclusion criteria (51 published and 16 registered or ongoing clinical trials). Among published studies, 10 employed randomized or double-blind controlled designs, 4 were case studies, and the remainder comprised cross-sectional surveys, qualitative interviews, or observational cohorts. The majority (47/51) investigated non-clinical populations such as healthy volunteers or self-selected microdosers, while 4 studies examined clinical populations, including major depressive disorder, anxiety, chronic pain, and post-traumatic stress disorder. Psilocybin and LSD were the most frequently studied compounds, appearing alone or in combination in over 90% of published work, with occasional inclusion of DMT, mescaline, or 1P-LSD. Across published data, microdosing was generally associated with self-reported improvements in mood, creativity, and wellbeing, although most studies lacked placebo control and relied on self-report measures. Adverse effects were infrequent and typically mild, such as transient anxiety or sleep disturbance. Among the 16 included clinical trials, 12 investigated psilocybin and 4 investigated LSD. The majority of trials employed randomized, double-blind, placebo-controlled designs; some used crossover or parallel-arm assignments, and two were conducted as open-label feasibility studies. Recent trials, including LSDDEP1 and LSDDEP2, evaluated microdosing in patients with major depressive disorder, marking a shift toward controlled testing in clinical populations.

Conclusions

The current evidence base for psychedelic microdosing remains preliminary but rapidly evolving. Observational and self-report studies suggest potential psychological benefits, yet methodological limitations preclude definitive conclusions about efficacy or safety. Ongoing randomized controlled trials are expected to provide more robust data to clarify dose-response relationships, therapeutic applications, and neurobiological mechanisms. Continued synthesis of these findings will be essential to guide future clinical and regulatory directions.

Schlagwörter

psychedelic microdosingserotonergic psychedelicspsilocybinLSDDMTmescalineayahuascamoodcreativitywell-being

Zitieren

APA

Chinna‐Meyyappan, A., Kaczmarek, E. S., Sajad, S., & Rosenblat, J. (2025). Microdosing Psychedelics: A Systematic Review of Human Studies and Registered Clinical Trials. Libraries and Cultural Resources (University of Calgary). https://doi.org/10.11575/prism/51859

Vancouver

Chinna‐Meyyappan A, Kaczmarek ES, Sajad S, Rosenblat J. Microdosing Psychedelics: A Systematic Review of Human Studies and Registered Clinical Trials. Libraries and Cultural Resources (University of Calgary). 2025. doi:10.11575/prism/51859

BibTeX
@article{ChinnaMeyyappan2025,
  author = {Chinna‐Meyyappan, Arun and Kaczmarek, Erica S. and Sajad, Sajad and Rosenblat, Joshua},
  title = {Microdosing Psychedelics: A Systematic Review of Human Studies and Registered Clinical Trials},
  journal = {Libraries and Cultural Resources (University of Calgary)},
  year = {2025},
  doi = {10.11575/prism/51859}
}
Kostenlos starten →